🔴 Tscan Therapeutics is trading 6.27% down today after pausing Phase 3 ALLOHA-2 enrollment over insufficient capital

Tscan Therapeutics is trading 6.27% down at $0.36 after pausing further Phase 3 ALLOHA-2 enrollment because of insufficient capital.

• On September 2, 2026, the company redirected resources toward preclinical solid-tumor programs while tracking already-enrolled patients.
• Restructuring included an approximately 75% workforce reduction, intensifying concerns about funding and the loss of its primary near-term clinical catalyst.
• Shares had fallen 42.80% to $0.38 on September 2, 2026, while broader biotechnology stocks gained, making company-specific financing and trial news the dominant explanation.